Neoadjuvant chemotherapy with or without oxaliplatin after short-course radiotherapy in high-risk rectal cancer: A subgroup analysis from a prospective study.
Neoadjuvant chemotherapy
Oxaliplatin
Rectal cancer
Journal
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
ISSN: 1507-1367
Titre abrégé: Rep Pract Oncol Radiother
Pays: Poland
ID NLM: 100885761
Informations de publication
Date de publication:
Historique:
received:
26
06
2020
revised:
28
07
2020
accepted:
11
08
2020
entrez:
4
1
2021
pubmed:
5
1
2021
medline:
5
1
2021
Statut:
ppublish
Résumé
To evaluate the role of oxaliplatin in neoadjuvant chemotherapy delivered after short-course irradiation. Using oxaliplatin in the above setting is uncertain. A subgroup of 136 patients managed by short-course radiotherapy and 3 cycles of consolidation chemotherapy within the framework of a randomised study was included in this post-hoc analysis. Sixty-seven patients received FOLFOX4 (oxaliplatin group) while oxaliplatin was omitted in the second period of accrual in 69 patients because of protocol amendment (fluorouracil-only group). Grade 3+ acute toxicity from neoadjuvant treatment was observed in 30% of patients in the oxaliplatin group vs. 16% in the fluorouracil-only group ( Our findings do not support adding oxaliplatin to three cycles of chemotherapy delivered after short-course irradiation.
Sections du résumé
AIM
OBJECTIVE
To evaluate the role of oxaliplatin in neoadjuvant chemotherapy delivered after short-course irradiation.
BACKGROUND
BACKGROUND
Using oxaliplatin in the above setting is uncertain.
PATIENTS AND METHODS
METHODS
A subgroup of 136 patients managed by short-course radiotherapy and 3 cycles of consolidation chemotherapy within the framework of a randomised study was included in this post-hoc analysis. Sixty-seven patients received FOLFOX4 (oxaliplatin group) while oxaliplatin was omitted in the second period of accrual in 69 patients because of protocol amendment (fluorouracil-only group).
RESULTS
RESULTS
Grade 3+ acute toxicity from neoadjuvant treatment was observed in 30% of patients in the oxaliplatin group vs. 16% in the fluorouracil-only group (
CONCLUSION
CONCLUSIONS
Our findings do not support adding oxaliplatin to three cycles of chemotherapy delivered after short-course irradiation.
Identifiants
pubmed: 33390858
doi: 10.1016/j.rpor.2020.08.002
pii: S1507-1367(20)30110-3
pmc: PMC7772602
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1017-1022Informations de copyright
© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
None
Références
J Clin Oncol. 2014 Jun 20;32(18):1927-34
pubmed: 24799484
Radiother Oncol. 2013 May;107(2):171-7
pubmed: 23590986
Br J Surg. 2013 Jul;100(8):E1-33
pubmed: 23901427
J Clin Oncol. 2019 Dec 1;37(34):3212-3222
pubmed: 31150315
Eur J Cancer. 2012 Aug;48(12):1781-90
pubmed: 22507892
BMC Cancer. 2013 Jun 07;13:279
pubmed: 23742033
J Natl Cancer Inst. 2019 Sep 1;111(9):887-902
pubmed: 31077329
J Clin Oncol. 2010 Apr 1;28(10):1638-44
pubmed: 20194850
J Clin Oncol. 2011 Jul 10;29(20):2773-80
pubmed: 21606427
Radiother Oncol. 2019 May;134:110-118
pubmed: 31005204
Ann Oncol. 2016 May;27(5):834-42
pubmed: 26884592
J Clin Oncol. 2019 Dec 1;37(34):3223-3233
pubmed: 31557064
J Natl Cancer Inst. 2015 Sep 14;107(11):
pubmed: 26374429
Eur J Surg Oncol. 2016 Dec;42(12):1859-1865
pubmed: 27546011
Lancet Oncol. 2012 Jul;13(7):679-87
pubmed: 22627104
Dis Colon Rectum. 2018 Oct;61(10):1146-1155
pubmed: 30192323
J Clin Oncol. 2009 Jul 1;27(19):3109-16
pubmed: 19451431
Chin J Cancer Res. 2015 Dec;27(6):588-96
pubmed: 26752933
Ann Surg. 2019 Jan;269(1):102-107
pubmed: 28742703
Ann Oncol. 2019 Aug 1;30(8):1298-1303
pubmed: 31192355
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv263
pubmed: 29741565